{"id":562491,"date":"2021-09-09T18:00:02","date_gmt":"2021-09-09T18:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=562491"},"modified":"2021-09-09T18:00:02","modified_gmt":"2021-09-09T18:00:02","slug":"with-the-influx-of-pharmaceutical-and-medtech-companies-along-with-the-novel-therapies-and-devices-the-chronic-venous-insufficiency-pipeline-is-booming","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/with-the-influx-of-pharmaceutical-and-medtech-companies-along-with-the-novel-therapies-and-devices-the-chronic-venous-insufficiency-pipeline-is-booming_562491.html","title":{"rendered":"With the influx of pharmaceutical and Medtech companies along with the novel therapies and devices, the Chronic Venous Insufficiency pipeline is booming"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1631188143.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"With the influx of pharmaceutical and Medtech companies along with the novel therapies and devices, the Chronic Venous Insufficiency pipeline is booming\" src=\"https:\/\/www.abnewswire.com\/uploads\/1631188143.png\" alt=\"With the influx of pharmaceutical and Medtech companies along with the novel therapies and devices, the Chronic Venous Insufficiency pipeline is booming\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Chronic Venous Insufficiency Pipeline <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s Chronic Venous Insufficiency pipeline report provides an in-depth analysis of the current clinical development landscape and growth prospects for the Chronic Venous Insufficiency industry. The disease summary and Chronic Venous Insufficiency therapy instructions are included in a complete depiction of the Chronic Venous Insufficiency pipeline landscape.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/905d76a04484a04709e9fe07fa3c8594.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-venous-insufficiency-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chronic Venous Insufficiency pipeline report<\/a><\/strong> provides an in-depth analysis of the current clinical development landscape and growth prospects for the Chronic Venous Insufficiency industry. The disease summary and Chronic Venous Insufficiency therapy instructions are included in a complete depiction of the Chronic Venous Insufficiency pipeline landscape.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Important Findings from the Chronic Venous Insufficiency Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Chronic Venous Insufficiency pipeline comprises therapies, as well as devices that are in different stages of the clinical phase, include <strong>Sulodexide, TR 987, P-TEV, EndoVenous Valve System (EVVS), InnoVein Valve Treatment, BioVena, VenoValve,<\/strong> and others that are anticipated to launch in the upcoming year and join the Chronic Venous Insufficiency treatment market soon.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key MedTech and pharmaceutical companies involved in developing novel therapies and medical devices for Chronic Venous Insufficiency include <strong>Alfasigma, SerenaGroup, Verigraft AB, Venarum Medical, Innovein, Venari Medical, Hancock Jaffe Laboratories,<\/strong> among others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chronic Venous Insufficiency pipeline therapies that are in late phases i.e Phase III include <strong>Sulodexide (Alfasigma),<\/strong> and others whereas <strong>TR 987 (SerenaGroup)<\/strong> is in Phase II of clinical trials for Chronic Venous Insufficiency treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>P-TEV<\/strong> is being developed and investigated in Phase I studies by <strong>Verigraft AB<\/strong> for Chronic Venous Insufficiency treatment.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Request for the sample to reach out for more @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-venous-insufficiency-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chronic Venous Insufficiency Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Chronic Venous Insufficiency (CVI) is a term used to describe lower extremity edema, skin trophic changes, and discomfort caused by venous hypertension. The pathophysiology of chronic venous insufficiency is caused by either reflux (backward flow) or obstruction of venous blood flow. Chronic venous insufficiency can develop as a result of long-term valvular incompetence in the superficial veins, deep veins, or perforating veins that connect them. The end result is venous hypertension of the lower extremities in all cases.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency Symptoms<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The most common Chronic Venous Insufficiency symptoms are:<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tight feeling in calves or itchy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Painful legs<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Swelling in legs or ankles<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Painful leg cramps or muscle spasms<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Varicose veins<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leg ulcers<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Chronic Venous Insufficiency treatment focuses on controlling the retrograde flow of blood, venous pooling, and the complications associated with these pathophysiologic processes. Conservative treatment consists of dietary changes, compression therapy with devices, and the administration of venoactive drugs (venopharmaceuticals).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>TR 987: SerenaGroup<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">TR-987 (formerly GLYC-101) is an insoluble, microparticulate (13)(16)-glucan extracted from yeast cells in a specific configuration and size. TR-987&#8217;s active pharmaceutical ingredient is Glucoprime, a type of glucan known as particulate (1&rarr;3)(1&rarr;6)-&beta;-glucan.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phase II<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>NCT03154619:<\/strong> SerenaGroup, in collaboration with TR Therapeutics, launched a multi-center, randomized, double-blind, placebo-controlled study in November 2016 to assess the efficacy of TR 987 gel in the treatment of chronic venous insufficiency ulcers.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency Pipeline Analysis: Medical Device Profile<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>VenoValve: Hancock Jaffe Laboratories<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">VenoValve is a bioprosthetic venous valve that improves chronic lower extremity venous reflux via an open surgical procedure. The company is conducting a prospective, non-blind, single-arm, multicenter study to evaluate the safety and efficacy of the VenoValve, which is surgically implanted into the deep venous system to treat patients with deep venous valvular insufficiency.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency Pipeline Therapies\/Devices and Key Companies<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sulodexide: Alfasigma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TR 987: SerenaGroup<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">P-TEV: Verigraft AB<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">EndoVenous Valve System (EVVS): Venarum Medical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">InnoVein Valve Treatment: Innovein<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BioVena: Venari Medical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">VenoValve: Hancock Jaffe Laboratories<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">For more information on the emerging drugs\/devices and companies, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-venous-insufficiency-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chronic Venous Insufficiency Clinical Trails<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Product Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monotherapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Combination Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Stage<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discovery<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-Clinical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase I<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase II<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase III<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-registration<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Route of Administration<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inhalation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Molecule Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small Molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Stem Cell Therapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Targets<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immune System<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple Kinase<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Protease<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Mechanism of Action<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Protease Inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunomodulatory<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple Kinase Inhibitor<\/p>\n<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency Medical Device Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Stage<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Clinical<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Patient Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pediatric<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Adult<\/p>\n<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> Global<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency Key Players:<\/strong> Alfasigma, SerenaGroup, Verigraft AB, Venarum Medical, Innovein, Venari Medical, Hancock Jaffe Laboratories, among others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chronic Venous Insufficiency Pipeline Therapies\/Devices:<\/strong> Sulodexide, TR 987, P-TEV, EndoVenous Valve System (EVVS), InnoVein Valve Treatment, BioVena, VenoValve, and others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"94\" \/>\n<col width=\"530\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency: Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Late Stage Products (Pre-registration)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Late Stage Products (Phase&nbsp; III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Mid Stage Products (Phase&nbsp; II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Early Stage Products (Phase&nbsp; I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Pre-clinical and Discovery Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Pipeline Medical devices: Company Profiles<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Medical Device Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency- Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Chronic Venous Insufficiency- Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key questions answered in the Chronic Venous Insufficiency Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">What are the available treatments for Chronic Venous Insufficiency?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many pharmaceutical and Medtech companies are developing treatments for Chronic Venous Insufficiency?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Which of these firms&#8217; pharmaceuticals is the most widely used?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many Chronic Venous Insufficiency medications\/devices does each company produce?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many drugs\/devices for Chronic Venous Insufficiency are in the early, mid, or late stages of development?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many of the currently being developed therapies\/devices can be used alone or in combination with other treatments?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">What are the most important industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices affecting Chronic Venous Insufficiency?<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/exocrine-pancreatic-insufficiency-epi-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Exocrine Pancreatic Insufficiency Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a comprehensive analysis of Exocrine Pancreatic Insufficiency pipeline therapies and key companies including <strong>Digestive Care, Inc., AzurRx BioPharma, Inc., Abbott, Orlando Health, Inc.,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=with-the-influx-of-pharmaceutical-and-medtech-companies-along-with-the-novel-therapies-and-devices-the-chronic-venous-insufficiency-pipeline-is-booming\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=with-the-influx-of-pharmaceutical-and-medtech-companies-along-with-the-novel-therapies-and-devices-the-chronic-venous-insufficiency-pipeline-is-booming\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic Venous Insufficiency Pipeline DelveInsight&#8217;s Chronic Venous Insufficiency pipeline report provides an in-depth analysis of the current clinical development landscape and growth prospects for the Chronic Venous Insufficiency industry. The disease summary and Chronic Venous Insufficiency therapy instructions are included &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/with-the-influx-of-pharmaceutical-and-medtech-companies-along-with-the-novel-therapies-and-devices-the-chronic-venous-insufficiency-pipeline-is-booming_562491.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,411,403,404],"tags":[],"class_list":["post-562491","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Technology","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=562491"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562491\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=562491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=562491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=562491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}